Access to Medicines Related News
Medical cannabis and the patient experience in the UK
It’s the most socially disruptive phenomenon of the new millennium - medical cannabis is sweeping the planet and patient experience could possibly be improving,...
What more can be done to enable patients to access medical cannabis prescriptions?
“The National Health Service has not issued one prescription since November” – Professor Mike Barnes discusses patient accessibility (or lack thereof) to medical cannabis...
Priorities for breast cancer resources questioned after global HER2 testing survey
A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer,...
Results through research: shaping the future of medical cannabis
Discover how, together, EMMAC Life Sciences and Imperial College London are advancing our understanding of the therapeutic properties of medical cannabis for a range...
A budding industry: How EMMAC Life Sciences is growing the medical cannabis industry across...
EMMAC Life Sciences’ Antonio Costanzo discusses the booming medical cannabis industry in Europe and EMMAC’s role in its future.
As investment and interest in the...
Learn the challenges and opportunities in the Canadian cannabis market
What should companies be aware of when moving into Canada’s rapidly growing legal cannabis market? Tricia Kuhl and Chris Nyberg, of law firm Blakes,...
How are companies providing services to Australia’s medicinal cannabis industry?
CEO of Anspec, Peter Comerford provides an insight into the burgeoning landscape of the medicinal cannabis industry in Australia and Anspec’s role in its...
#DontTaxMedicine – the campaign to make medical cannabis affordable
Medical cannabis is a prescription drug in Canada – so why are patients being forced to pay tax on it? CFAMM president and CEO...
Let’s talk about Little Green Pharma and medicinal cannabis
Discover Little Green Pharma – an innovator and pioneer in Australian-grown, cultivated and exported medicinal cannabis.
Managing director Fleta Solomon explains how Little Green Pharma...
Medicinal cannabis for MS in the UK – a long way from reality
Despite the change in law, the government has failed on its promise to deliver access to potentially life-changing medicinal cannabis - The MS Society...
TILRAY: the medical cannabis research global leader
Medical cannabis is rapidly gaining momentum across the globe, and Tilray Inc. is pioneering the production, research, and distribution of medical cannabis.
This ebook explores...
Available on prescription? The complicated picture of medical cannabis in the UK
It is doctors’ conservatism and not government regulations that is holding back patient access to medical cannabis in the UK, says Professor Mike Barnes.
In...
From highly priced medicines to Medicines That Matter
Highly priced medicines represent a significant public health challenge. Global health advocate Ella Weggen shares how Wemos is responding through its dedicated project Medicines...
Will a no-deal Brexit impact insulin supply getting into the UK?
Diabetes UK has responded to recent concerns from the chair of the Medicines and Healthcare products Regulatory Authority (MHRA), Sir Michael Rawlins, that a...
The Austrian MPS Society’s Therapy Week – more than just therapy
In July, Health Europa saw first-hand how the Austrian MPS Society’s Therapy Week brings patients and their families together for more than just a...
The developing role of hospital pharmacists
Joan Peppard, the immediate past president of the European Association of Hospital Pharmacists, discusses the evolution of the hospital pharmacy specialist.
The prescribing of medication...
Positive progress in antimicrobial resistance prevention across the globe
Countries are making substantial progress in tackling the ever growing issue of antimicrobial resistance (AMR), however, serious gaps still remain and require urgent action,...
One million Iraqis could see loss of health facilities due to funding gap
Critical health facilities in Iraq are facing closures due to a lack of funding, which leaves nearly one million people without access to basic...
The pharmaceutical industry responds to the Brexit White Paper
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (APBI) and BioIndustry Association’s (BIA) chief executive Steve Bates have issued a...
EMA: Ramp up efforts to ensure EU medicine supply post-Brexit
The European Medicines Agency (EMA) has warned that some companies need to take further action to safeguard the EU medicine supply once the UK...